Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone's antifbrotic activity

Hypertension

Volumn 71, Issue 4, 2018, Pages 599-608

  Grune, Jana ^a,b,c   Beyhoff, Niklas ^b,c   Smeir, Elia ^b,c   Chudek, Remigiusz ^b   Blumrich, Annelie ^b,c   Ban, Zsofa ^b,c   Brix, Sarah ^b   Betz, Iris R ^b,c   Schupp, Michael ^b   Foryst Ludwig, Anna ^b,c   Klopfleisch, Robert ^d   Stawowy, Philipp ^a   Houtman, René ^e   Kolkhof, Peter ^f   Kintscher, Ulrich ^b,c  

^a DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^d FREIE UNIVERSITÄT BERLIN   (Germany)

^e PamGene International   (Netherlands)

^f BAYER AG   (Germany)

Author keywords

Aldosterone; Fbrosis; Isoproterenol; Mineralocorticoids; Pharmacology; Speckle tracking echocardiography

Indexed keywords

ALDOSTERONE; ANTIFIBROTIC AGENT; EPLERENONE; FINERENONE; ISOPRENALINE; MINERALOCORTICOID RECEPTOR; TENASCIN; MINERALOCORTICOID ANTAGONIST; NAPHTHYRIDINE DERIVATIVE; TENASCIN X;

ALDOSTERONE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIAC MUSCLE CELL; CELL INVASION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; HEART LEFT VENTRICLE MASS; HEART MUSCLE FIBROSIS; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPECKLE TRACKING ECHOCARDIOGRAPHY; ANIMAL; BIOAVAILABILITY; DISEASE MODEL; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HEART FAILURE; METABOLISM;

ANIMALS; BIOLOGICAL AVAILABILITY; DISEASE MODELS, ANIMAL; EPLERENONE; GENE EXPRESSION REGULATION; HEART FAILURE; MICE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MYOCYTES, CARDIAC; NAPHTHYRIDINES; TENASCIN;

EID: 85051675046     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.117.10360     Document Type: Article

References (27)

1. Mentz RJ, Bakris GL, Waeber B, McMurray JJ, Gheorghiade M, Ruilope LM, Maggioni AP, Swedberg K, Piña IL, Fiuzat M, O'Connor CM, Zannad F, Pitt B. The past, present and future of renin-angiotensin aldosterone system inhibition. Int J Cardiol. 2013;167:1677-1687. doi: 10.1016/j.ijcard.2012.10.007.
2. Bauersachs J, Jaisser F, Toto R. Mineralocorticoid receptor activa-tion and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertension. 2015;65:257-263. doi: 10.1161/HYPERTENSIONAHA.114.04488.
3. Kolkhof P, Bärfacker L. 30 years of the mineralocorticoid receptor: min-eralocorticoid receptor antagonists: 60 years of research and development. J Endocrinol. 2017;234:T125-T140. doi: 10.1530/JOE-16-0600.
4. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. 1990;82:1730-1736.
5. Fuller PJ, Young MJ. Mechanisms of mineralocorticoid action. Hypertension. 2005;46:1227-1235. doi: 10.1161/01.HYP.0000193502.77417.17.
6. Ponikowski P, Voors AA, Anker SD, et al; Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129-2200. doi: 10.1093/eurheartj/ehw128.
7. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Effcacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321. doi: 10.1056/NEJMoa030207.
8. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717. doi: 10.1056/NEJM199909023411001.
9. Bramlage P, Swift SL, Thoenes M, Minguet J, Ferrero C, Schmieder RE. Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease. Eur J Heart Fail. 2016;18:28-37. doi: 10.1002/ejhf.444.
10. Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, Nowack C, Kolkhof P, Kim SY, Zannad F. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34:2453-2463. doi: 10.1093/eurheartj/eht187.
11. Grune J, Benz V, Brix S, Salatzki J, Blumrich A, Höft B, Klopfeisch R, Foryst-Ludwig A, Kolkhof P, Kintscher U. Steroidal and nonsteroidal min-eralocorticoid receptor antagonists cause differential cardiac gene expression in pressure overload-induced cardiac hypertrophy. J Cardiovasc Pharmacol. 2016;67:402-411. doi: 10.1097/FJC.0000000000000366.
12. Beyhoff N, Brix S, Betz IR, Klopfeisch R, Foryst-Ludwig A, Krannich A, Stawowy P, Knebel F, Grune J, Kintscher U. Application of speckle-tracking echocardiography in an experimental model of isolated subendo-cardial damage. J Am Soc Echocardiogr. 2017;30:1239-1250 e1232.
13. Fejes-Tóth G, Náray-Fejes-Tóth A. Early aldosterone-regulated genes in cardiomyocytes: clues to cardiac remodeling? Endocrinology. 2007;148:1502-1510. doi: 10.1210/en.2006-1438.
14. Atucha E, Zalachoras I, van den Heuvel JK, van Weert LT, Melchers D, Mol IM, Belanoff JK, Houtman R, Hunt H, Roozendaal B, Meijer OC. A mixed glucocorticoid/mineralocorticoid selective modulator with dominant antagonism in the male rat brain. Endocrinology. 2015;156:4105-4114. doi: 10.1210/en.2015-1390.
15. Bristow J, Carey W, Egging D, Schalkwijk J. Tenascin-X, collagen, elas-tin, and the Ehlers-Danlos syndrome. Am J Med Genet C Semin Med Genet. 2005;139C:24-30. doi: 10.1002/ajmg.c.30071.
16. Jönsson-Rylander AC, Nilsson T, Fritsche-Danielson R, Hammarström A, Behrendt M, Andersson JO, Lindgren K, Andersson AK, Wallbrandt P, Rosengren B, Brodin P, Thelin A, Westin A, Hurt-Camejo E, Lee-Søgaard CH. Role of ADAMTS-1 in atherosclerosis: remodeling of carotid artery, immunohistochemistry, and proteolysis of versican. Arterioscler Thromb Vasc Biol. 2005;25:180-185. doi: 10.1161/01. ATV.0000150045.27127.37.
17. Gronemeyer H, Gustafsson JA, Laudet V. Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov. 2004;3:950-964. doi: 10.1038/nrd1551.
18. Hultman ML, Krasnoperova NV, Li S, Du S, Xia C, Dietz JD, Lala DS, Welsch DJ, Hu X. The ligand-dependent interaction of mineralocorticoid receptor with coactivator and corepressor peptides suggests multiple activation mechanisms. Mol Endocrinol. 2005;19:1460-1473. doi: 10.1210/me.2004-0537.
19. Yang J, Young MJ. The mineralocorticoid receptor and its coregulators. J Mol Endocrinol. 2009;43:53-64. doi: 10.1677/JME-09-0031.
20. Samuel CS, Bodaragama H, Chew JY, Widdop RE, Royce SG, Hewitson TD. Serelaxin is a more effcacious antifbrotic than enalapril in an experimental model of heart disease. Hypertension. 2014;64:315-322. doi: 10.1161/HYPERTENSIONAHA.114.03594.
21. Montagutelli X. Effect of the genetic background on the phenotype of mouse mutations. J Am Soc Nephrol. 2000;11(suppl 16):S101-S105.
22. Kolkhof P, Delbeck M, Kretschmer A, Steinke W, Hartmann E, Bärfacker L, Eitner F, Albrecht-Küpper B, Schäfer S. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat car-diorenal injury. J Cardiovasc Pharmacol. 2014;64:69-78. doi: 10.1097/FJC.0000000000000091.
23. Chiovaro F, Chiquet-Ehrismann R, Chiquet M. Transcriptional regu-lation of tenascin genes. Cell Adh Migr. 2015;9:34-47. doi: 10.1080/19336918.2015.1008333.
24. Bärfacker L, Kuhl A, Hillisch A, Grosser R, Figueroa-Pérez S, Heckroth H, Nitsche A, Ergüden JK, Gielen-Haertwig H, Schlemmer KH, Mittendorf J, Paulsen H, Platzek J, Kolkhof P. Discovery of BAY 94-8862: a nonste-roidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. Chem Med Chem. 2012;7:1385-1403. doi: 10.1002/cmdc.201200081.
25. Fagart J, Hillisch A, Huyet J, Bärfacker L, Fay M, Pleiss U, Pook E, Schäfer S, Rafestin-Oblin ME, Kolkhof P. A new mode of mineralocorti-coid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem. 2010;285:29932-29940. doi: 10.1074/jbc.M110.131342.
26. Amazit L, Le Billan F, Kolkhof P, Lamribet K, Viengchareun S, Fay MR, Khan JA, Hillisch A, Lombès M, Rafestin-Oblin ME, Fagart J. Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1. J Biol Chem. 2015;290:21876-21889. doi: 10.1074/jbc.M115.657957.
27. Filippatos G, Anker SD, Böhm M, et al. A randomized controlled study of fnerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J. 2016;37:2105-2114. doi: 10.1093/eurheartj/ehw132.